
    
      Open-label single center trial to study improvements in symptom bother and quality of life in
      OAB patients self titrating solifenacin 5mg and 10 mg. The study was designed to reflect real
      world conditions in typical male and female OAB patients presenting for treatment. After
      eligibility was confirmed, subjects completed a number of questionnaires which include
      patient perception of bladder condition (PPBC)12, Overactive Bladder Questionaire (OAB-q13),
      visual analog scale (VAS) 0-100 assessing bother of urge incontinence, urgency, frequency and
      nocturia over the past week.
    
  